Publications

Publications

Filter Results: (25) Arrow Down

Show Results For

← Page 2 of 25 Results
  • 18 Apr 2018
  • First Look

First Look at New Research and Ideas, April 18, 2018

product upon entry, however only a few biosimilars have been approved in the U.S. since 2015, thereby largely preserving biologics from competition. We analyze European markets, which have had biosimilar... View Details
Keywords: Sean Silverthorne
  • 21 Aug 2018
  • First Look

New Research and Ideas, August 21, 2018

growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby largely... View Details
Keywords: Dina Gerdeman
  • 07 Jul 2015
  • First Look

First Look: July 7, 2015

biosimilars (BS), which are essentially "me-too" products. There appear to be sound reasons to explore this related diversification: innovation is getting harder, regulators are intent on encouraging BS, and Amgen needs renewed... View Details
Keywords: Sean Silverthorne
  • 06 Jun 2017
  • First Look

First Look at New Research and Ideas: June 6, 2017

regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging View Details
Keywords: Sean Silverthorne
  • 14 Mar 2017
  • First Look

First Look at New Research, March 14

Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/317023-PDF-ENG Harvard Business School Case 517-054 QuintilesIMS: Biosimilars Marketing in England QuintilesIMS was a leading healthcare consulting firm best known for its data... View Details
Keywords: Sean Silverthorne